ArticleFrontiers in immunology2020
A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- A Pfs48/45-based vaccine to block Plasmodium falciparum transmission: phase 1, open-label, clinical trial.BMC medicine · 2024Trial
- A combined designed CSP and Pfs48/45 infection and transmission blocking vaccine for malaria.NPJ vaccines · 2025Article
- 50-Fold Adjuvant and 20-Fold Antigen Vaccine Dose Sparing from Nanoliposome Display of a Stabilized Malarial Protein Antigen.ACS nano · 2025Article
- Production and Purification of Plasmodium Circumsporozoite Protein in Lactococcus lactis.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Article
- Design of a stabilized non-glycosylated Pfs48/45 antigen enables a potent malaria transmission-blocking nanoparticle vaccine.NPJ vaccines · 2023Article
- B-Cell Epitope Mapping of theVaccines · 2023Article
- Highly potent, naturally acquired human monoclonal antibodies against Pfs48/45 block Plasmodium falciparum transmission to mosquitoes.Immunity · 2023Article
- Cloning and Recombinant Protein Expression in Lactococcus lactis.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults.The Lancet. Infectious diseases · 2022Article
- Article
- 40 Years of Pfs48/45 Research as a Transmission-Blocking Vaccine Target of Plasmodium falciparum Malaria.The American journal of tropical medicine and hygiene · 2022Article
- Vaccine co-display of CSP and Pfs230 on liposomes targeting two Plasmodium falciparum differentiation stages.Communications biology · 2022Article
- Method for Production of Cysteine-Rich Proteins in Lactococcus lactis Expression System.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Review
- Heterologous Expression and Evaluation of NovelFrontiers in immunology · 2022Article
- Rare Alleles and Signatures of Selection on the Immunodominant Domains of Pfs230 and Pfs48/45 in Malaria Parasites From Western Kenya.Frontiers in genetics · 2022Article
- Transmission-Blocking Strategies Against Malaria Parasites During Their Mosquito Stages.Frontiers in cellular and infection microbiology · 2022Review
- Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine.NPJ vaccines · 2021Article
- Immune mechanisms targeting malaria transmission: opportunities for vaccine development.Expert review of vaccinesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cysteine-rich Pfs48/45 protein, a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.